Sign in Subscribe

crc-research

A collection of 723 issues

Cetuximab Rechallenge Tested Against Regorafenib in RAS Wild-Type mCRC

Skip to content The CRC Digest ◆ TRIAL DATA Cetuximab Rechallenge Tested Against Regorafenib in RAS Wild-Type mCRC A single-center randomized trial evaluated cetuximab plus irinotecan rechallenge versus regorafenib in RAS wild-type, microsatellite-stable metastatic colorectal cancer patients who had previously responded to then progressed off cetuximab, with progression-free survival as the

CRISPR Screens Reveal How MSI-H Tumors Depend on WRN Helicase

Skip to content The CRC Digest ◇ RESEARCH CRISPR Screens Reveal How MSI-H Tumors Depend on WRN Helicase Genome-wide CRISPR screens identified SMARCAL1 as a key modulator of WRN dependency in MSI-H colorectal cancer, with loss of SMARCAL1 rendering cells resistant to the WRN inhibitor HRO761. The findings shed light on

Review highlights accessible blood-based biomarkers for CRC detection

Skip to content The CRC Digest ◇ RESEARCH Review highlights accessible blood-based biomarkers for CRC detection A systematic review synthesizes circulating transcriptomic and proteomic biomarkers detectable by widely available RT-PCR and ELISA platforms, aiming to bridge the gap between high-throughput research and clinically scalable diagnostics. (Crit Rev Clin Lab Sci) This

Machine learning model predicts liver metastasis risk after colorectal cancer surgery

Skip to content The CRC Digest ◇ RESEARCH Machine learning model predicts liver metastasis risk after colorectal cancer surgery A multicenter study developed an AI-integrated model using clinical, laboratory, and CT imaging data to predict which stage I–III CRC patients will develop metachronous liver metastasis within 5 years after radical

Dual KRAS Y96C/Y96S resistance mutations emerge after KRAS G12C inhibitor therapy

Skip to content The CRC Digest ◇ RESEARCH Dual KRAS Y96C/Y96S resistance mutations emerge after KRAS G12C inhibitor therapy Liquid biopsy detected concurrent Y96S and Y96C mutations in a patient with KRAS G12C-mutated metastatic CRC who progressed after 9.3 months of KRAS G12C inhibitor monotherapy; these polyclonal alterations were

First-line immunotherapy outperforms chemotherapy in MSI-H/dMMR metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA First-line immunotherapy outperforms chemotherapy in MSI-H/dMMR metastatic colorectal cancer A meta-analysis of phase III trials confirms immune checkpoint inhibitors show superior progression-free and overall survival compared to standard chemotherapy as first-line treatment for patients with MSI-H or dMMR metastatic disease. (J

CRC Research Update — July 20, 2026

Today's colorectal cancer research highlights

Anastomotic leakage shows minimal long-term impact on quality of life after rectal cancer surgery

Skip to content The CRC Digest ♥ LIVING WITH CRC Anastomotic leakage shows minimal long-term impact on quality of life after rectal cancer surgery A Swedish population-based study found that while anastomotic leakage after anterior resection is associated with long-term bowel dysfunction, its impact on health-related quality of life 3 years

DR5-Lig3 feedback loop may shape immunotherapy response in dMMR colorectal cancer

Skip to content The CRC Digest ◇ RESEARCH DR5-Lig3 feedback loop may shape immunotherapy response in dMMR colorectal cancer New research identifies a molecular pathway that may influence how mismatch repair-deficient tumors respond to immunotherapy. (BioPharm International) This content is informational only and does not constitute medical advice. Always consult your

Circulating tumor DNA may identify which patients benefit from chemotherapy after liver metastasis surgery

Skip to content The CRC Digest ◆ TRIAL DATA Circulating tumor DNA may identify which patients benefit from chemotherapy after liver metastasis surgery The phase II GALAXY study (298 patients) found that ctDNA testing 2-10 weeks after surgery for colorectal liver metastases could help predict which patients are most likely to